Shanghai Junshi Biosciences Co., Ltd. provided earnings guidance for the year ended December 31, 2023. According to preliminary calculations by the financial department of the Company, it is estimated that the operating revenue for 2023 would be approximately RMB1,541 million, representing an increase of approximately RMB 87.5073 million compared with the same period of the previous year or a year-on-year increase of approximately 6.02%. it is estimated that the research and development ("R&D") expenses for 2023 would be approximately RMB 1,964 million, representing a decrease of approximately RMB 420.3734 million compared with the same period of the previous year or a year- on-year decrease of approximately 17.63%.

it is estimated that the net loss attributable to the owners of the parent company for 2023 would be approximately RMB 2,250 million, representing a decrease in loss of approximately RMB 138.0499 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 5.78%. it is estimated that the net loss attributable to the owners of the parent company after deducting non-recurring gains and losses for 2023 would be approximately RMB 2,279 million, representing a decrease in loss of approximately RMB 171.1976 million compared with the same period of the previous year or a year-on-year decrease in loss of approximately 6.99%.